C. Fiche, Pathologie Insuffisance Cardiaque Aiguë et Chronique, 2016.

O. Chioncel, M. Lainscak, P. M. Seferovic, S. D. Anker, M. G. Crespo-leiro et al., Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry, Eur J Heart Fail, vol.19, issue.12, pp.1574-85, 2017.

K. Dharmarajan, A. F. Hsieh, V. T. Kulkarni, Z. Lin, J. S. Ross et al., Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study, BMJ. 5 févr, vol.350, p.411, 2015.

S. F. Jencks, M. V. Williams, and E. A. Coleman, Rehospitalizations among Patients in the Medicare Fee-for-Service Program, N Engl J Med. 2 avr, vol.360, issue.14, pp.1418-1446, 2009.

C. M. O'connor, A. B. Miller, J. Blair, M. A. Konstam, P. Wedge et al., Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program, Am Heart J. mai, vol.159, issue.5, pp.841-849, 2010.

M. Gheorghiade, M. Vaduganathan, G. C. Fonarow, and R. O. Bonow, Rehospitalization for Heart Failure: Problems and Perspectives, J Am Coll Cardiol. 29 janv, vol.61, issue.4, pp.391-403, 2013.

. Ors, Observation Régionale de Santé -Evolution et projection des maladies chroniques, 2016.

P. Tuppin, A. Cuerq, C. De-peretti, A. Fagot-campagna, N. Danchin et al., First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up, Arch Cardiovasc Dis, vol.106, issue.11, pp.570-85, 2013.

, Améliorer la qualité du système de santé et maîtriser les dépenses -Propositions de l'Assurance Maladie pour 2019, 2018.

W. Stokes and L. Nunn, A New Effective Diuretic-Lasix, Br Med J, vol.2, issue.5414, pp.910-914, 1964.

W. B. Stason, P. J. Cannon, H. Ho, J. H. Laragh, and . Furosemide, A clinical evaluation of its diuretic action, Circulation. nov, vol.34, issue.5, pp.910-930, 1966.

D. L. Vargo, W. G. Kramer, P. K. Black, W. B. Smith, T. Serpas et al., Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure, Clin Pharmacol Ther. juin, vol.57, issue.6, pp.601-610, 1995.

K. A. Wargo and W. M. Banta, A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother, vol.43, pp.1836-1883, 2009.

J. J. Dinicolantonio, Should torsemide be the loop diuretic of choice in systolic heart failure?, Future Cardiol. sept, vol.8, issue.5, pp.707-735, 2012.

B. Bikdeli, K. M. Strait, K. Dharmarajan, C. Partovian, S. G. Coca et al., Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?, J Am Coll Cardiol. 9 avr, vol.61, issue.14, pp.1549-50, 2013.

J. Buggey, R. J. Mentz, B. Pitt, E. L. Eisenstein, K. J. Anstrom et al., A reappraisal of loop diuretic choice in heart failure patients, Am Heart J. mars, vol.169, issue.3, pp.323-356, 2015.

K. Dikshit, J. K. Vyden, J. S. Forrester, K. Chatterjee, R. Prakash et al., Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction, N Engl J Med. 24 mai, vol.288, issue.21, pp.1087-90, 1973.

C. M. Huang, A. J. Atkinson, M. Levin, N. W. Levin, and A. Quintanilla, Pharmacokinetics of furosemide in advanced renal failure, Clin Pharmacol Ther, vol.16, issue.4, pp.659-66, 1974.

M. M. Hammarlund, L. K. Paalzow, and B. Odlind, Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis, Eur J Clin Pharmacol, vol.26, issue.2, pp.197-207, 1984.

M. Hammarlund-udenaes and L. Z. Benet, Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update, J Pharmacokinet Biopharm. févr, vol.17, issue.1, pp.1-46, 1989.

M. Oppermann, P. B. Hansen, H. Castrop, and J. Schnermann, Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice, Am J Physiol Renal Physiol. juill, vol.293, issue.1, pp.279-287, 2007.

G. S. Francis, R. M. Siegel, S. R. Goldsmith, M. T. Olivari, T. B. Levine et al., Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis, Ann Intern Med. juill, vol.103, issue.1, pp.1-6, 1985.

N. A. Gilotra, O. Princewill, B. Marino, I. S. Okwuosa, J. Chasler et al., Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure, JACC Heart Fail. janv, vol.6, issue.1, pp.65-70, 2018.

D. A. Sica, P. Muntendam, R. L. Myers, J. M. Ter-maaten, M. E. Sale et al., Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution, JACC Basic Transl Sci. févr, vol.3, issue.1, pp.25-34, 2018.

B. P. Chen, Loop diuretics: comparison of torsemide, furosemide, and bumetanide, Conn Med. juin, vol.60, issue.6, pp.343-348, 1996.

G. M. Felker and R. J. Mentz, Diuretics and Ultrafiltration in Acute Decompensated Heart Failure, J Am Coll Cardiol. juin, vol.59, issue.24, pp.2145-53, 2012.

D. A. Sica, B. Carter, W. Cushman, L. Hamm, L. Thiazide et al., J Clin Hypertens, vol.13, issue.9, pp.639-682, 2011.

B. Beermann and M. Groschinsky-grind, Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure, Br J Clin Pharmacol. juin, vol.7, issue.6, pp.579-83, 1979.

B. Beermann, M. Groschinsky-grind, and A. Rosén, Absorption, metabolism, and excretion of hydrochlorothiazide, Clin Pharmacol Ther. mai, vol.19, issue.5, pp.531-538, 1976.

R. H. Barbhaiya, R. B. Patel, H. P. Corrick-west, R. S. Joslin, and P. G. Welling, Comparative bioavailability and pharmacokinetics of hydrochlorothiazide from oral tablet dosage forms, determined by plasma level and urinary excretion methods, Biopharm Drug Dispos. déc, vol.3, issue.4, pp.329-365, 1982.

L. L. Herman, K. Bashir, and . Hydrochlorothiazide, Treasure Island (FL): StatPearls Publishing, StatPearls [Internet, 2018.

E. J. Hoorn, J. H. Nelson, J. A. Mccormick, and D. H. Ellison, The WNK kinase network regulating sodium, potassium, and blood pressure, J Am Soc Nephrol JASN. avr, vol.22, issue.4, pp.605-619, 2011.

M. V. Sorensen, S. Grossmann, M. Roesinger, N. Gresko, A. P. Todkar et al., Rapid dephosphorylation of the renal sodium chloride cotransporter in response to oral potassium intake in mice, Kidney Int. mai, vol.83, issue.5, pp.811-835, 2013.

A. Pottegård, J. Hallas, M. Olesen, M. T. Svendsen, L. A. Habel et al., Hydrochlorothiazide use is strongly associated with risk of lip cancer, J Intern Med, vol.282, issue.4, pp.322-353, 2017.

S. A. Pedersen, D. Gaist, S. Schmidt, L. R. Hölmich, S. Friis et al., Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide casecontrol study from Denmark, J Am Acad Dermatol, vol.78, issue.4, pp.673-681, 2018.

P. Kolkhof and L. Bärfacker, 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development, J Endocrinol. juill, vol.234, issue.1, pp.125-165, 2017.

A. Struthers, H. Krum, and G. H. Williams, A comparison of the aldosterone-blocking agents eplerenone and spironolactone, Clin Cardiol. avr, vol.31, issue.4, pp.153-161, 2008.

J. Yang and M. J. Young, Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences, Curr Opin Pharmacol. avr, vol.27, pp.78-85, 2016.

D. Vukadinovi?, D. Lavall, A. N. Vukadinovi?, B. Pitt, S. Wagenpfeil et al., True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis, Am Heart J. juin, vol.188, pp.99-108, 2017.

M. Lainscak, F. Pelliccia, G. Rosano, C. Vitale, M. Schiariti et al., Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone, Int J Cardiol. 1 déc, vol.200, pp.25-34, 2015.

B. Pitt and P. Rossignol, The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure, Expert Opin Drug Saf. mai, vol.15, issue.5, pp.659-65, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01760512

F. H. Verbrugge, M. Dupont, P. Steels, L. Grieten, M. Malbrain et al., Abdominal Contributions to Cardiorenal Dysfunction in Congestive Heart Failure, J Am Coll Cardiol. 6 août, vol.62, issue.6, pp.485-95, 2013.

P. Martens, P. Nijst, and W. Mullens, Current Approach to Decongestive Therapy in Acute Heart Failure, Curr Heart Fail Rep. déc, vol.12, issue.6, pp.367-78, 2015.

S. I. Chaudhry, Y. Wang, J. Concato, T. M. Gill, and H. M. Krumholz, Patterns of weight change preceding hospitalization for heart failure, Circulation, vol.116, issue.14, pp.1549-54, 2007.

S. Dovancescu, P. Pellicori, T. Mabote, A. Torabi, A. L. Clark et al., The effects of short-term omission of daily medication on the pathophysiology of heart failure, Eur J Heart Fail, vol.19, issue.5, pp.643-652, 2017.

W. L. Miller, Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed, Circ Heart Fail, vol.9, issue.8, p.2922, 2016.

A. L. Clark, A. Coats, H. Krum, H. A. Katus, P. Mohacsi et al., Effect of betaadrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial, J Cachexia Sarcopenia Muscle. août, vol.8, issue.4, pp.549-56, 2017.

G. Loncar, J. Springer, M. Anker, W. Doehner, and M. Lainscak, Cardiac cachexia: hic et nunc: « hic et nunc » -here and now, Int J Cardiol. 15 déc, vol.201, pp.1-12, 2015.

M. Metra, B. Davison, L. Bettari, H. Sun, C. Edwards et al., Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function, Circ Heart Fail. janv, vol.5, issue.1, pp.54-62, 2012.

P. Rossignol, S. Masson, S. Barlera, N. Girerd, A. Castelnovo et al., Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials, Eur J Heart Fail. avr, vol.17, issue.4, pp.424-457, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01752255

A. P. Ambrosy, L. P. Cerbin, P. W. Armstrong, J. Butler, A. Coles et al., Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial, JACC Heart Fail, vol.5, issue.1, pp.1-13, 2017.

, Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Fa, PubMed -NCBI

J. M. Testani, M. A. Brisco, R. D. Kociol, D. Jacoby, L. Bellumkonda et al., Substantial Discrepancy Between Fluid and Weight Loss During Acute Decompensated Heart Failure Treatment, Am J Med. juill, vol.128, issue.7, pp.776-783, 2015.

A. P. Ambrosy, P. S. Pang, S. Khan, M. A. Konstam, G. C. Fonarow et al., Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial, Eur Heart J. mars, vol.34, issue.11, pp.835-878, 2013.

P. Pellicori, J. Cleland, J. Zhang, A. Kallvikbacka-bennett, A. Urbinati et al., Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure, Cardiovasc Drugs Ther. déc, vol.30, issue.6, pp.599-609, 2016.

M. Gheorghiade, G. Filippatos, D. Luca, L. Burnett, and J. , Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment, Am J Med. 1 déc, vol.119, issue.12, pp.3-10, 2006.

S. Coiro, P. Rossignol, A. G. Carluccio, E. Alunni, G. Murrone et al., Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure, Eur J Heart Fail, vol.17, issue.11, pp.1172-81, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01757897

M. Gheorghiade, D. Luca, L. Fonarow, G. C. Filippatos, G. Metra et al., Pathophysiologic targets in the early phase of acute heart failure syndromes, Am J Cardiol. 19 sept, vol.96, issue.6A, pp.11-17, 2005.

A. Lala, S. E. Mcnulty, R. J. Mentz, S. M. Dunlay, J. M. Vader et al., Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF), Circ Heart Fail. juill, vol.8, issue.4, pp.741-749, 2015.

J. Rubio-gracia, B. G. Demissei, J. M. Ter-maaten, J. G. Cleland, O. Connor et al., Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure, Int J Cardiol. 1 mai, vol.258, pp.185-91, 2018.

M. Gheorghiade, F. Follath, P. Ponikowski, J. H. Barsuk, J. Blair et al., Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine, Eur J Heart Fail. mai, vol.12, issue.5, pp.423-456, 2010.

S. F. Nagueh, O. A. Smiseth, C. P. Appleton, B. F. Byrd, H. Dokainish et al., Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. avr, vol.29, issue.4, pp.277-314, 2016.

S. F. Nagueh, Non-invasive assessment of left ventricular filling pressure, Eur J Heart Fail, vol.20, issue.1, pp.38-48, 2018.

G. Volpicelli, S. Skurzak, E. Boero, G. Carpinteri, M. Tengattini et al., Lung ultrasound predicts well extravascular lung water but is of limited usefulness in the prediction of wedge pressure, Anesthesiology. août, vol.121, issue.2, pp.320-327, 2014.

W. Mullens, A. G. Borowski, R. J. Curtin, J. D. Thomas, and W. H. Tang, Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure, Circulation. 6 janv, vol.119, issue.1, pp.62-70, 2009.

A. P. Ambrosy, A. S. Bhatt, D. Gallup, K. J. Anstrom, J. Butler et al., Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network), Am J Cardiol. 1 juill, vol.120, issue.1, pp.98-105, 2017.

L. Van-aelst, M. Arrigo, R. Placido, E. Akiyama, N. Girerd et al., Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion, Eur J Heart Fail, vol.20, issue.4, pp.738-785, 2018.

C. Binanay, R. M. Califf, V. Hasselblad, O. Connor, C. M. Shah et al., Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial, JAMA, vol.294, issue.13, pp.1625-1658, 2005.

D. Aronson, Z. Abassi, E. Allon, and A. J. Burger, Fluid loss, venous congestion, and worsening renal function in acute decompensated heart failure, Eur J Heart Fail. 1 juin, vol.15, issue.6, pp.637-680, 2013.

S. Stienen, K. Salah, A. H. Moons, A. L. Bakx, P. Van-pol et al., NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NTProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?), Circulation. 17 avr, vol.137, issue.16, pp.1671-83, 2018.

A. S. Desai, Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long, Circulation. 29 janv, vol.127, issue.4, pp.509-525, 2013.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. Cleland et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J. 14 juill, vol.37, issue.27, pp.2129-200, 2016.

C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey et al., ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, Circulation. 1 janv, 2017.

J. M. Testani, J. Chen, B. D. Mccauley, S. E. Kimmel, and R. P. Shannon, Potential Effects of Aggressive Decongestion during the Treatment of Decompensated Heart Failure on Renal Function and Survival, Circulation. 20 juill, vol.122, issue.3, pp.265-72, 2010.

T. Breidthardt, Z. M. Weidmann, R. Twerenbold, C. Gantenbein, F. Stallone et al., Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function, Eur J Heart Fail, vol.19, issue.2, pp.226-262, 2017.

S. J. Greene, M. Gheorghiade, M. Vaduganathan, A. P. Ambrosy, R. J. Mentz et al., Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial, Eur J Heart Fail. déc, vol.15, issue.12, pp.1401-1412, 2013.

J. M. Testani, M. A. Brisco, J. Chen, B. D. Mccauley, C. R. Parikh et al., Timing of Hemoconcentration during Treatment of Acute Decompensated Heart Failure and Subsequent Survival: Importance of sustained decongestion, J Am Coll Cardiol. 6 août, vol.62, issue.6, pp.516-540, 2013.

K. Duarte, J. Monnez, A. E. Pitt, B. Zannad, F. Rossignol et al., Prognostic Value of Estimated Plasma Volume in Heart Failure, JACC Heart Fail, vol.3, issue.11, pp.886-93, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01236515

S. R. Hudson, D. Chan, and L. L. Ng, Change in plasma volume and prognosis in acute decompensated heart failure: an observational cohort study, J R Soc Med. sept, vol.109, issue.9, pp.337-383, 2016.

J. R. Balderston, K. B. Shah, S. C. Paciulli, and Z. M. Gertz, Usefulness of Estimated Plasma Volume at Postdischarge Follow-Up to Predict Recurrent Events in Patients With Heart Failure, Am J Cardiol, vol.122, issue.7, pp.1191-1195, 2018.

M. Kobayashi, P. Rossignol, J. P. Ferreira, I. Aragão, Y. Paku et al., Prognostic value of estimated plasma volume in acute heart failure in three cohort studies, Clin Res Cardiol Off J Ger Card Soc, 2018.

T. Chouihed, P. Rossignol, A. Bassand, K. Duarte, M. Kobayashi et al., Diagnostic and prognostic value of plasma volume status at emergency department admission in dyspneic patients: results from the PARADISE cohort, Clin Res Cardiol Off J Ger Card Soc, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02138898

T. Ahmad, K. Jackson, V. S. Rao, W. Tang, M. A. Brisco-bacik et al., Worsening Renal Function in Acute Heart Failure Patients Undergoing Aggressive Diuresis is Not Associated with Tubular Injury, Circulation. 19 janv, 2018.

D. Kremer, J. M. Ter-maaten, and A. A. Voors, Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure, Eur J Heart Fail, vol.20, issue.9, pp.1363-1368, 2018.

W. H. Self, A. B. Storrow, O. Hartmann, T. W. Barrett, G. J. Fermann et al., Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure, Am J Emerg Med. févr, vol.34, issue.2, pp.257-62, 2016.

P. Caironi, R. Latini, J. Struck, O. Hartmann, A. Bergmann et al., Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis, Chest, vol.152, issue.2, pp.312-332, 2017.

H. Tolppanen, M. Rivas-lasarte, J. Lassus, J. Sans-roselló, O. Hartmann et al., Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock, Ann Intensive Care. déc, vol.7, issue.1, p.6, 2017.

J. Núñez, P. Llàcer, V. Bertomeu-gonzález, M. J. Bosch, P. Merlos et al., Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study, JACC Heart Fail, vol.4, issue.11, pp.833-876, 2016.

H. Kaya, R. Kurt, O. Beton, A. Zorlu, H. Yucel et al., Cancer Antigen 125 is Associated with Length of Stay in Patients with Acute Heart Failure, Tex Heart Inst J. févr, vol.44, issue.1, pp.22-30, 2017.

P. Llàcer, A. Bayés-genís, and J. Núñez, Carbohydrate antigen 125 in heart failure. New era in the monitoring and control of treatment, Med Clin (Barc), 2018.

E. Gayat, A. Caillard, S. Laribi, C. Mueller, M. Sadoune et al., Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure, Int J Cardiol, vol.199, pp.241-248, 2015.

W. Mullens, K. Damman, V. Harjola, A. Mebazaa, H. Rocca et al., The use of diuretics in heart failure with congestion -a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail

D. Sur,

N. Girerd, M. Seronde, S. Coiro, T. Chouihed, P. Bilbault et al., Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey, JACC Heart Fail. avr, vol.6, issue.4, pp.273-85, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01847385

W. F. Peacock, M. R. Costanzo, D. Marco, T. Lopatin, M. Wynne et al., Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry, Cardiology, vol.113, issue.1, pp.12-21, 2009.

. Solvd-investigators, S. Yusuf, B. Pitt, C. E. Davis, W. B. Hood et al., Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, vol.01, issue.5, pp.293-302, 1991.

, Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure, Control Clin Trials. févr, vol.17, issue.1, pp.77-97, 1996.

G. C. Fonarow, W. G. Stough, W. T. Abraham, N. M. Albert, M. Gheorghiade et al., Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry, J Am Coll Cardiol. 21 août, vol.50, issue.8, pp.768-77, 2007.

R. Faris, M. Flather, H. Purcell, M. Henein, P. Poole-wilson et al., Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials, Int J Cardiol. 1 févr, vol.82, issue.2, pp.149-58, 2002.

O. Laszczy?ska, M. Severo, F. Friões, P. Lourenço, S. Silva et al., Prognostic Effect of the Dose of Loop Diuretic Over 5 Years in Chronic Heart Failure, J Card Fail. 1 août, vol.23, issue.8, pp.589-93, 2017.

V. Hasselblad, G. Stough, W. Shah, M. R. Lokhnygina, Y. et al., Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial, Eur J Heart Fail, vol.9, issue.10, pp.1064-1073, 2007.

H. M. Abdel-qadir, J. V. Tu, L. Yun, P. C. Austin, G. E. Newton et al., Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization, Am Heart J. 1 août, vol.160, issue.2, pp.264-271, 2010.

B. Pitt, F. Zannad, W. J. Remme, R. Cody, A. Castaigne et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med. 2 sept, vol.341, issue.10, pp.709-726, 1999.

N. M. Berbenetz and M. Mrkobrada, Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis, BMC Cardiovasc Disord, vol.01, issue.1, p.246, 2016.

J. P. Ferreira, P. Rossignol, J. Machu, A. Sharma, N. Girerd et al., Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF, Eur J Heart Fail, vol.19, issue.10, pp.1284-93, 2017.

O. Vardeny, B. Claggett, I. Anand, P. Rossignol, A. S. Desai et al., Incidence, predictors, and outcomes related to hypo-and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist, Circ Heart Fail. juill, vol.7, issue.4, pp.573-582, 2014.

A. Pandey, S. Garg, S. A. Matulevicius, A. M. Shah, J. Garg et al., Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review, J Am Heart Assoc, vol.4, issue.10, p.2137, 2015.

B. Williams, G. Mancia, W. Spiering, A. Rosei, E. Azizi et al., , 2018.

. Esc/esh, Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension, J Hypertens, vol.36, issue.10, pp.1953-2041, 2018.

, Guide du Parcours de Soins Insuffisance Cardiaque -Haute Autorité de Santé -Service des maladies chroniques et des dispositifs d'accompagnement des maladesJuin, HAS, 2014.

E. Galve, A. Mallol, R. Catalan, J. Palet, S. Méndez et al., Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction, Eur J Heart Fail. août, vol.7, issue.5, pp.892-900, 2005.

M. R. Costanzo, L. W. Stevenson, P. B. Adamson, A. S. Desai, J. T. Heywood et al., Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring, JACC Heart Fail. 1 mai, vol.4, issue.5, pp.333-377, 2016.

P. Martens, F. H. Verbrugge, P. Nijst, M. Dupont, and W. Mullens, Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions, Am J Cardiol. 15 juill, vol.120, issue.2, pp.267-73, 2017.

C. J. Kapelios, E. Kaldara, A. Ntalianis, N. E. Pantsios, C. Repasos et al., Lowering furosemide dose in stable chronic heart failure patients with reduced ejection fraction is not accompanied by decompensation: A randomized study, Int J Cardiol. 15 déc, vol.177, issue.2, pp.690-692, 2014.

P. Martens, F. H. Verbrugge, L. Boonen, P. Nijst, M. Dupont et al., Value of routine investigations to predict loop diuretic down-titration success in stable heart failure, Int J Cardiol. 1 janv, vol.250, pp.171-176, 2018.

E. Van-riet, A. W. Hoes, A. Limburg, M. Landman, H. Van-der-hoeven et al., Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion, Eur J Heart Fail. juill, vol.16, issue.7, pp.772-779, 2014.

R. Bright, Cases and Observations, Illustrative of Renal Disease, Accompanied with the Secretion of Albuminous Urine. Br Foreign Med Rev, vol.10, pp.301-330, 1840.

J. T. Heywood, G. C. Fonarow, M. R. Costanzo, V. S. Mathur, J. R. Wigneswaran et al., High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database, J Card Fail. août, vol.13, issue.6, pp.422-452, 2007.

C. Ronco, P. Mccullough, S. D. Anker, I. Anand, N. Aspromonte et al., Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative, Eur Heart J. mars, vol.31, issue.6, pp.703-714, 2010.

W. Vandenberghe, S. Gevaert, J. A. Kellum, S. M. Bagshaw, H. Peperstraete et al., Acute Kidney Injury in Cardiorenal Syndrome Type 1 Patients: A Systematic Review and Meta-Analysis, Cardiorenal Med. févr, vol.6, issue.2, pp.116-144, 2016.

T. A. Mavrakanas, A. Khattak, K. Singh, and D. M. Charytan, Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography, Clin J Am Soc Nephrol CJASN, vol.12, issue.10, pp.1624-1657, 2017.

K. Damman, W. Tang, J. M. Testani, and J. Mcmurray, Terminology and definition of changes renal function in heart failure, Eur Heart J. 21 déc, vol.35, issue.48, pp.3413-3419, 2014.

A. Shirakabe, N. Hata, N. Kobayashi, H. Okazaki, M. Matsushita et al., Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure, ESC Heart Fail, vol.5, issue.3, pp.322-353, 2018.

R. Van-kimmenade, T. J. Cate, and H. Brunner-la-rocca, Worsening Renal Function in Heart Failure: It Takes 2 to Tangle *, J Am Coll Cardiol. 3 janv, vol.69, issue.1, pp.70-72, 2017.

N. Kuster, M. Moréna, A. Bargnoux, H. Leray, L. Chenine et al.,

, Ann Biol Clin (Paris). août, vol.71, issue.4, pp.409-427, 2013.

L. L. Ng, I. B. Squire, D. Jones, T. H. Cao, D. Chan et al., Renal Dysfunction, and Prognosis in Patients With Acute Heart Failure: A GREAT Network Study, J Am Coll Cardiol. 3 janv, vol.69, issue.1, pp.56-69, 2017.

J. G. Kingma, D. Simard, J. R. Rouleau, B. Drolet, and C. Simard, The Physiopathology of Cardiorenal Syndrome: A Review of the Potential Contributions of Inflammation, J Cardiovasc Dev Dis, vol.4, issue.4, 2017.

C. Ronco, M. Cicoira, and P. A. Mccullough, Cardiorenal Syndrome Type 1: Pathophysiological Crosstalk Leading to Combined Heart and Kidney Dysfunction in the Setting of Acutely Decompensated Heart Failure, J Am Coll Cardiol, vol.60, issue.12, pp.1031-1073, 2012.

A. Nohria, V. Hasselblad, A. Stebbins, D. F. Pauly, G. C. Fonarow et al., J Am Coll Cardiol. 1 avr, vol.51, issue.13, pp.1268-74, 2008.

W. Mullens, Z. Abrahams, G. S. Francis, G. Sokos, D. O. Taylor et al., Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure, J Am Coll Cardiol. 17 févr, vol.53, issue.7, pp.589-96, 2009.

K. Damman, V. M. Van-deursen, G. Navis, A. A. Voors, D. J. Van-veldhuisen et al., Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease, J Am Coll Cardiol. 17 févr, vol.53, issue.7, pp.582-590, 2009.

M. Guglin, A. Rivero, F. Matar, and M. Garcia, Renal dysfunction in heart failure is due to congestion but not low output, Clin Cardiol. févr, vol.34, issue.2, pp.113-119, 2011.

H. H. Chen, K. J. Anstrom, M. M. Givertz, L. W. Stevenson, M. J. Semigran et al., Low Dose Dopamine or Low Dose Nesiritide in Acute Heart Failure with Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial, JAMA J Am Med Assoc. 18 déc, vol.310, issue.23, pp.2533-2576, 2013.

L. B. Cooper, R. J. Mentz, S. R. Stevens, G. M. Felker, C. Lombardi et al., Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?, J Card Fail. mars, vol.22, issue.3, pp.182-191, 2016.

J. S. Hanberg, K. Sury, F. P. Wilson, M. A. Brisco, T. Ahmad et al., Reduced Cardiac Index is Not the Dominant Driver of Renal Dysfunction in Heart Failure, J Am Coll Cardiol. 17 mai, vol.67, pp.2199-208, 2016.

K. Damman, M. Valente, A. A. Voors, O. Connor, C. M. Van-veldhuisen et al., Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis, Eur Heart J. févr, vol.35, issue.7, pp.455-69, 2014.

M. Dupont, K. Shrestha, D. Singh, A. Awad, C. Kovach et al., Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure, Eur J Heart Fail. juin, vol.14, issue.6, pp.597-604, 2012.

M. A. Brisco, M. R. Zile, J. S. Hanberg, F. P. Wilson, C. R. Parikh et al., Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial, J Card Fail, vol.22, issue.10, pp.753-60, 2016.

P. Ruggenenti and G. Remuzzi, Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney, Eur Heart J. oct, vol.32, issue.20, pp.2476-2484, 2011.

K. Damman and J. M. Testani, The kidney in heart failure: an update, Eur Heart J. 14 juin, vol.36, issue.23, pp.1437-1481, 2015.

D. H. Ellison, The physiologic basis of diuretic synergism: its role in treating diuretic resistance, Ann Intern Med. 15 mai, vol.114, issue.10, pp.886-94, 1991.

L. De-bruyne, Mechanisms and management of diuretic resistance in congestive heart failure, Postgrad Med J. mai, vol.79, issue.931, pp.268-71, 2003.

D. Kumar and R. Bagarhatta, Fractional excretion of sodium and its association with prognosis of decompensated heart failure patients, J Clin Diagn Res JCDR. avr, vol.9, issue.4, pp.1-03, 2015.

J. M. Ter-maaten, A. M. Dunning, M. Valente, K. Damman, J. A. Ezekowitz et al., Diuretic response in acute heart failure-an analysis from ASCEND-HF, Am Heart J. août, vol.170, issue.2, pp.313-334, 2015.

G. W. Neuberg, A. B. Miller, O. Connor, C. M. Belkin, R. N. Carson et al., Diuretic resistance predicts mortality in patients with advanced heart failure, Am Heart J. juill, vol.144, issue.1, pp.31-39, 2002.

B. K. Krämer, F. Schweda, and G. A. Riegger, Diuretic treatment and diuretic resistance in heart failure, Am J Med. janv, vol.106, issue.1, pp.90-96, 1999.

S. L. Ravnan, M. C. Ravnan, and P. C. Deedwania, Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure, Congest Heart Fail Greenwich Conn. avr, vol.8, issue.2, pp.80-85, 2002.

D. H. Ellison and G. M. Felker, Diuretic Treatment in Heart Failure, N Engl J Med, vol.377, issue.20, pp.1964-75, 2017.

J. C. Jentzer, T. A. Dewald, and A. F. Hernandez, Combination of loop diuretics with thiazidetype diuretics in heart failure, J Am Coll Cardiol, vol.56, issue.2, pp.1527-1561, 2010.

D. C. Brater, R. Seiwell, S. Anderson, A. Burdette, G. J. Dehmer et al., Absorption and disposition of furosemide in congestive heart failure, Kidney Int. août, vol.22, issue.2, pp.171-177, 1982.

D. C. Brater, P. Chennavasin, and R. Seiwell, Furosemide in patients with heart failure: shift in dose-response curves, Clin Pharmacol Ther. août, vol.28, issue.2, pp.182-188, 1980.

D. C. Brater, Resistance to loop diuretics. Why it happens and what to do about it, Drugs. nov, vol.30, issue.5, pp.427-470, 1985.

M. Hasegawa, H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi et al., Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide, J Am Soc Nephrol JASN. janv, vol.18, issue.1, pp.37-45, 2007.

V. Vallon, T. Rieg, S. Y. Ahn, W. Wu, S. A. Eraly et al., Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics, Am J Physiol Renal Physiol. avr, vol.294, issue.4, pp.867-873, 2008.

B. Kaissling, S. Bachmann, and W. Kriz, Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment, Am J Physiol. mars, vol.248, issue.3, pp.374-381, 1985.

D. H. Ellison, H. Velázquez, and F. S. Wright, Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion, J Clin Invest. janv, vol.83, issue.1, pp.113-139, 1989.

V. S. Rao, N. Planavsky, J. S. Hanberg, T. Ahmad, M. A. Brisco-bacik et al., Compensatory Distal Reabsorption Drives Diuretic Resistance in Human Heart Failure, J Am Soc Nephrol JASN, vol.28, issue.11, pp.3414-3438, 2017.

J. Loffing, L. Hir, M. Kaissling, and B. , Modulation of salt transport rate affects DNA synthesis in vivo in rat renal tubules, Kidney Int. juin, vol.47, issue.6, pp.1615-1638, 1995.

A. S. Terker, C. Zhang, J. A. Mccormick, R. A. Lazelle, C. Zhang et al., Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride, Cell Metab. 6 janv, vol.21, issue.1, pp.39-50, 2015.

Y. Apte, R. Bellomo, S. Warrillow, D. Goldsmith, M. Gillies et al., Pilot randomised double-blind controlled trial of high-dose spironolactone in critically ill patients receiving a frusemide infusion, Crit Care Resusc J Australas Acad Crit Care Med. déc, vol.10, issue.4, pp.306-317, 2008.

, Pulmonary SMF is the creator of P org H is an assistant professor of, Vermont CCM at the U of. PulmCrit-Overcoming occult diuretic resistance: Achieving diuresis without dehydration

E. Project, , 2016.

D. L. Kuchar and M. F. O'rourke, High dose furosemide in refractory cardiac failure, Eur Heart J. nov, vol.6, issue.11, pp.954-962, 1985.

P. G. Gerlag and J. J. Van-meijel, High-dose furosemide in the treatment of refractory congestive heart failure, Arch Intern Med. févr, vol.148, issue.2, pp.286-91, 1988.

G. M. Felker, K. L. Lee, D. A. Bull, M. M. Redfield, L. W. Stevenson et al., Diuretic strategies in patients with acute decompensated heart failure, N Engl J Med. 3 mars, vol.364, issue.9, pp.797-805, 2011.

J. S. Hanberg, W. Tang, F. P. Wilson, S. G. Coca, T. Ahmad et al., An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial, Int J Cardiol. 15 août, vol.241, pp.277-82, 2017.

R. J. Mentz, S. R. Stevens, A. D. Devore, A. Lala, J. M. Vader et al., Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure, JACC Heart Fail. févr, vol.3, issue.2, pp.97-107, 2015.

S. Eshaghian, T. B. Horwich, and G. C. Fonarow, Relation of loop diuretic dose to mortality in advanced heart failure, Am J Cardiol. 15 juin, vol.97, issue.12, pp.1759-64, 2006.

L. M. Mielniczuk, S. W. Tsang, A. S. Desai, A. Nohria, E. F. Lewis et al., The Association Between High-Dose Diuretics and Clinical Stability in Ambulatory Chronic Heart Failure Patients, J Card Fail. 1 juin, vol.14, issue.5, pp.388-93, 2008.

K. Damman, J. Kjekshus, J. Wikstrand, J. Cleland, M. Komajda et al., Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction, Eur J Heart Fail. mars, vol.18, issue.3, pp.328-364, 2016.

S. I. Jardim, L. Ramos-dos-santos, I. Araújo, F. Marques, P. Branco et al., A 2018 overview of diuretic resistance in heart failure, Rev Port Cardiol, vol.37, issue.11, pp.935-980, 2018.

D. W. Rudy, J. R. Voelker, P. K. Greene, F. A. Esparza, and D. C. Brater, Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy, Ann Intern Med. 1 sept, vol.115, issue.5, pp.360-366, 1991.

M. Lahav, A. Regev, P. Ra'anani, and T. E. , Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure, Chest. sept, vol.102, issue.3, pp.725-756, 1992.

J. J. Van-meyel, P. Smits, F. G. Russel, P. G. Gerlag, Y. Tan et al., Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers, Clin Pharmacol Ther. avr, vol.51, issue.4, pp.440-444, 1992.

S. J. Martin and L. H. Danziger, Continuous infusion of loop diuretics in the critically ill: a review of the literature, Crit Care Med. août, vol.22, issue.8, pp.1323-1332, 1994.

E. Aaser, L. Gullestad, S. Tølløfsrud, J. Lundberg, C. Hall et al., Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure, Scand J Clin Lab Invest. juill, vol.57, issue.4, pp.361-368, 1997.

D. Salvador, F. E. Punzalan, N. R. Rey, M. R. Bernado, and M. D. Nablo, Continuous infusion versus bolus injection of loop diuretics in congestive heart failure, Cochrane Database of Systematic Reviews

, , 2005.

A. Palazzuoli, M. Pellegrini, G. Ruocco, G. Martini, B. Franci et al., Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial, Crit Care, vol.18, issue.3, p.134, 2014.

F. H. Verbrugge, P. Nijst, M. Dupont, J. Penders, W. Tang et al., Urinary composition during decongestive treatment in heart failure with reduced ejection fraction, Circ Heart Fail. sept, vol.7, issue.5, pp.766-72, 2014.

H. Knauf and E. Mutschler, Low-dose segmental blockade of the nephron rather than highdose diuretic monotherapy, Eur J Clin Pharmacol, vol.44, issue.1, pp.63-68, 1993.

M. A. Brisco-bacik, T. Maaten, J. M. Houser, S. R. Vedage, N. A. Rao et al., Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis, J Am Heart Assoc. 18 sept, vol.7, issue.18, p.9149, 2018.

J. C. Trullàs, J. L. Morales-rull, J. Casado, A. Freitas-ramírez, L. Manzano et al., Rationale and Design of the "Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial:" A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Combined Diuretic Therapy (Loop Diuretics With Thiazide-Type Diuretics) Among Patients With Decompensated Heart Failure, J Card Fail. 1 juill, vol.22, issue.7, pp.529-565, 2016.

J. Butler, A. F. Hernandez, K. J. Anstrom, A. Kalogeropoulos, M. M. Redfield et al., Rationale and Design of the Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy in Heart Failure (ATHENA-HF) Trial, JACC Heart Fail. sept, vol.4, issue.9, pp.726-761, 2016.

F. H. Verbrugge, P. Martens, K. Ameloot, V. Haemels, J. Penders et al., Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome, Acta Cardiol. 27 mars, pp.1-8, 2018.

W. Mullens, F. H. Verbrugge, P. Nijst, P. Martens, K. Tartaglia et al., Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial, Eur J Heart Fail, vol.20, issue.11, pp.1591-600, 2018.

F. H. Verbrugge, M. Dupont, P. B. Bertrand, P. Nijst, J. Penders et al., Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload, Acta Cardiol. juin, vol.70, issue.3, pp.265-73, 2015.

D. Singh, K. Shrestha, J. M. Testani, F. H. Verbrugge, M. Dupont et al., Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure, J Card Fail. juin, vol.20, issue.6, pp.392-401, 2014.

J. P. Ferreira, N. Girerd, P. Bettencourt-medeiros, M. Bento-ricardo, T. Almeida et al., Lack of Diuretic Efficiency (but Not Low Diuresis) Early in An Acutely Decompensated Heart Failure Episode Is Associated with Increased 180-Day Mortality, Cardiorenal Med. févr, vol.7, issue.2, pp.137-186, 2017.

J. M. Testani, J. S. Hanberg, S. Cheng, V. Rao, C. Onyebeke et al., Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure, Circ Heart Fail. janv, vol.9, issue.1, p.2370, 2016.

J. L. Grodin, S. Carter, B. A. Bart, S. R. Goldsmith, M. H. Drazner et al., Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a perprotocol analysis of CARRESS-HF, Eur J Heart Fail, vol.20, issue.7, pp.1148-56, 2018.

A. Al-naher, D. Wright, M. Devonald, and M. Pirmohamed, Renal function monitoring in heart failure -what is the optimal frequency? A narrative review, Br J Clin Pharmacol. janv, vol.84, issue.1, pp.5-17, 2018.

L. F. Buckley, D. M. Carter, L. Matta, J. W. Cheng, C. Stevens et al., Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit, JACC Heart Fail. 1 janv, vol.4, issue.1, pp.1-8, 2016.

L. F. Buckley, E. Seoane-vazquez, J. Cheng, A. Aldemerdash, I. M. Cooper et al., Comparison of Ambulatory, High-Dose, Intravenous Diuretic Therapy to Standard Hospitalization and Diuretic Therapy for Treatment of Acute Decompensated Heart Failure, Am J Cardiol, vol.118, issue.9, pp.1350-1355, 2016.

E. Colin-ramirez and J. A. Ezekowitz, Salt in the diet in patients with heart failure: what to recommend, Curr Opin Cardiol. mars, vol.31, issue.2, pp.196-203, 2016.

Y. Li, B. Fu, and X. Qian, Liberal versus restricted fluid administration in heart failure patients. A systematic review and meta-analysis of randomized trials, Int Heart J, vol.56, issue.2, pp.192-197, 2015.

E. Colin-ramirez, F. A. Mcalister, Y. Zheng, S. Sharma, and J. A. Ezekowitz, Changes in dietary intake and nutritional status associated with a significant reduction in sodium intake in patients with heart failure. A sub-analysis of the SODIUM-HF pilot study, Clin Nutr ESPEN, vol.11, pp.26-32, 2016.

B. Riegel, S. Lee, J. Hill, M. Daus, F. O. Baah et al., Patterns of adherence to diuretics, dietary sodium and fluid intake recommendations in adults with heart failure, Heart Lung, issue.9, 2019.

D. Sur,

C. Ezekowitz, J. A. , and S. Investigators, Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF), Am Heart J. nov, vol.205, pp.87-96, 2018.

M. R. Costanzo, J. T. Heywood, B. M. Massie, J. Iwashita, L. Henderson et al., A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease, Eur J Heart Fail. août, vol.14, issue.8, pp.922-952, 2012.

D. Hall, Are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure? Cardiol Clin, vol.19, pp.597-603, 2001.

P. S. Jhund, A. P. Davie, and J. J. Mcmurray, Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure, J Am Coll Cardiol. avr, vol.37, issue.5, pp.1234-1242, 2001.

A. S. Maisel, W. F. Peacock, N. Mcmullin, J. R. Fonarow, G. C. Wynne et al., Timing of Immunoreactive B-Type Natriuretic Peptide Levels and Treatment Delay in Acute Decompensated Heart Failure: An ADHERE (Acute Decompensated Heart Failure National Registry) Analysis, J Am Coll Cardiol. 12 août, vol.52, issue.7, pp.534-574, 2008.

N. Kagiyama and Y. Matsue, The time-to-treatment concept in acute heart failure: Lessons and implications from REALITY-AHF, Anatol J Cardiol. août, vol.20, issue.2, pp.125-134, 2018.

Y. Matsue, K. Damman, A. A. Voors, N. Kagiyama, T. Yamaguchi et al., Timeto-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure, J Am Coll Cardiol. 27 juin, vol.69, issue.25, pp.3042-51, 2017.

M. J. Ward, S. P. Collins, D. Liu, and C. M. Froehle, Preventable delays to intravenous furosemide administration in the emergency department prolong hospitalization for patients with acute heart failure, Int J Cardiol, vol.269, pp.207-219, 2018.

J. R. Catlin, C. B. Adams, D. J. Louie, M. D. Wilson, and E. N. Louie, Aggressive Versus Conservative Initial Diuretic Dosing in the Emergency Department for Acute Decompensated Heart Failure, Ann Pharmacother. janv, vol.52, issue.1, pp.26-31, 2018.

C. Mueller, A. Scholer, K. Laule-kilian, M. B. Schindler, C. Buser et al., Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea, N Engl J Med. 12 févr, vol.350, issue.7, pp.647-54, 2004.

G. W. Moe, J. Howlett, J. L. Januzzi, and H. Zowall, Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study, Circulation. 19 juin, vol.115, issue.24, pp.3103-3113, 2007.

F. H. Verbrugge, P. Steels, L. Grieten, P. Nijst, W. Tang et al., Hyponatremia in acute decompensated heart failure: depletion versus dilution, J Am Coll Cardiol. 10 févr, vol.65, issue.5, pp.480-92, 2015.

M. Gheorghiade, W. T. Abraham, N. M. Albert, G. Stough, W. Greenberg et al., Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry, Eur Heart J. avr, vol.28, issue.8, pp.980-988, 2007.

F. H. Verbrugge, J. L. Grodin, M. Wilfried, D. O. Taylor, R. C. Starling et al., Transient Hyponatremia during Hospitalization for Acute Heart Failure, Am J Med. juin, vol.129, issue.6, pp.620-627, 2016.

M. Konishi, G. Haraguchi, H. Ohigashi, T. Sasaoka, S. Yoshikawa et al., Progression of hyponatremia is associated with increased cardiac mortality in patients hospitalized for acute decompensated heart failure, J Card Fail. août, vol.18, issue.8, pp.620-625, 2012.

D. Rusinaru, C. Tribouilloy, C. Berry, A. M. Richards, G. A. Whalley et al., Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis( ?): Meta-Analysis Global Group in Chronic heart failure (MAGGIC), Eur J Heart Fail, vol.14, issue.10, pp.1139-1185, 2012.

M. A. Konstam, M. Gheorghiade, J. C. Burnett, L. Grinfeld, A. P. Maggioni et al., Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial, JAMA. 28 mars, vol.297, issue.12, pp.1319-1350, 2007.

J. Skogestad and J. M. Aronsen, Hypokalemia-Induced Arrhythmias and Heart Failure: New Insights and Implications for Therapy, vol.9, p.1500, 2018.

C. B. Bowling, B. Pitt, M. I. Ahmed, I. B. Aban, P. W. Sanders et al., Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies, Circ Heart Fail. mars, vol.3, issue.2, pp.253-60, 2010.

K. Salah, Y. M. Pinto, L. W. Eurlings, M. Metra, S. Stienen et al., Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis, Am Heart J. sept, vol.170, issue.3, pp.531-542, 2015.

M. Aldahl, A. Jensen, L. Davidsen, M. A. Eriksen, M. Hansen et al., Associations of serum potassium levels with mortality in chronic heart failure patients, Eur Heart J, vol.38, issue.38, pp.2890-2896, 2017.

M. L. Krogager, L. Eggers-kaas, K. Aasbjerg, R. N. Mortensen, L. Køber et al., Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction, Eur Heart J -Cardiovasc Pharmacother, vol.1, issue.4, pp.245-51, 2015.

I. Dørup, K. Skajaa, and N. K. Thybo, Oral magnesium supplementation restores the concentrations of magnesium, potassium and sodium-potassium pumps in skeletal muscle of patients receiving diuretic treatment, J Intern Med. févr, vol.233, issue.2, pp.117-140, 1993.

N. Cohen, I. Alon, D. Almoznino-sarafian, R. Zaidenstein, J. Weissgarten et al., Metabolic and clinical effects of oral magnesium supplementation in furosemidetreated patients with severe congestive heart failure, Clin Cardiol. juin, vol.23, issue.6, pp.433-439, 2000.

J. L. Grodin, J. Simon, R. Hachamovitch, Y. Wu, G. Jackson et al., Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure, J Am Coll Cardiol. 11 août, vol.66, issue.6, pp.659-66, 2015.

D. Ding, H. Liu, W. Qi, H. Jiang, Y. Li et al., Ototoxic effects and mechanisms of loop diuretics, J Otol. déc, vol.11, issue.4, pp.145-56, 2016.

J. L. Grodin, S. R. Stevens, L. De-las-fuentes, M. Kiernan, E. Y. Birati et al., Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure, J Card Fail. janv, vol.22, issue.1, pp.26-32, 2016.

B. A. Bart, S. R. Goldsmith, K. L. Lee, M. M. Givertz, C. M. O'connor et al., Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome, N Engl J Med. 13 déc, vol.367, issue.24, pp.2296-304, 2012.

J. H. Barsuk, R. A. Gordon, E. R. Cohen, W. G. Cotts, D. Malkenson et al., A Diuretic Protocol Increases Volume Removal and Reduces Readmissions Among Hospitalized Patients With Acute Decompensated Heart Failure, Congest Heart Fail. 1 mars, vol.19, issue.2, pp.53-60, 2013.

M. R. Costanzo, D. Negoianu, G. C. Fonarow, B. E. Jaski, B. A. Bart et al., Rationale and design of the Aquapheresis Versus Intravenous Diuretics and Hospitalization for Heart Failure (AVOID-HF) trial, Am Heart J. sept, vol.170, issue.3, pp.471-82, 2015.

M. R. Costanzo, D. Negoianu, B. E. Jaski, B. A. Bart, J. T. Heywood et al., Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure, JACC Heart Fail. 1 févr, vol.4, issue.2, pp.95-105, 2016.

, Protocolized Diuretic Strategy in Cardiorenal Failure -Study ResultsClinicalTrials.gov

M. R. Costanzo, C. Ronco, W. T. Abraham, P. Agostoni, J. Barasch et al., Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research, J Am Coll Cardiol. 16 mai, vol.69, pp.2428-2473, 2017.

B. A. Bart, A. Boyle, A. J. Bank, I. Anand, M. T. Olivari et al., Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial, J Am Coll Cardiol. 6 déc, vol.46, issue.11, pp.2043-2049, 2005.

M. R. Costanzo, M. E. Guglin, M. T. Saltzberg, M. L. Jessup, B. A. Bart et al., Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure, J Am Coll Cardiol. 13 févr, vol.49, issue.6, pp.675-83, 2007.

C. Giglioli, D. Landi, E. Cecchi, M. Chiostri, G. F. Gensini et al., Effects of ULTRAfiltration vs. DIureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study, Eur J Heart Fail. mars, vol.13, issue.3, pp.337-383, 2011.

J. Galindo-ocaña, J. Romero-mena, J. R. Castillo-ferrando, C. Aguilera-gonzález, M. Bernabeu-wittel et al., Subcutaneous furosemide as palliative treatment in patients with advanced and terminal-phase heart failure, BMJ Support Palliat Care. mars, vol.3, issue.1, pp.7-9, 2013.

L. B. Farless, N. Steil, B. R. Williams, and F. A. Bailey, Intermittent subcutaneous furosemide: parenteral diuretic rescue for hospice patients with congestive heart failure resistant to oral diuretic, Am J Hosp Palliat Care. déc, vol.30, issue.8, pp.791-793, 2013.

H. Zacharias, J. Raw, A. Nunn, S. Parsons, and M. Johnson, Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure, Palliat Med. sept, vol.25, issue.6, pp.658-63, 2011.

S. Paterna, D. Pasquale, P. Parrinello, G. Amato, P. Cardinale et al., Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure, Eur J Heart Fail. sept, vol.2, issue.3, pp.305-318, 2000.

A. Gabrielsen, P. Bie, N. H. Holstein-rathlou, N. J. Christensen, J. Warberg et al., Neuroendocrine and renal effects of intravascular volume expansion in compensated heart failure, Am J Physiol Regul Integr Comp Physiol. août, vol.281, issue.2, pp.459-467, 2001.

S. Paterna, D. Gaudio, F. , L. Rocca, V. Balistreri et al., Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure, Adv Ther, vol.32, issue.10, pp.971-82, 2015.

D. Vecchis, R. Esposito, C. Ariano, C. Cantatrione, and S. , Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature, Herz. mai, vol.40, issue.3, pp.423-458, 2015.

G. Lafrenière, P. Béliveau, J. Bégin, D. Simonyan, S. Côté et al., Effects of hypertonic saline solution on body weight and serum creatinine in patients with acute decompensated heart failure, World J Cardiol. 26 août, vol.9, issue.8, pp.685-92, 2017.

Y. Wan, L. Li, H. Niu, X. Ma, J. Yang et al., Impact of Compound Hypertonic Saline Solution on Decompensated Heart Failure, Int Heart J. 3 août, vol.58, issue.4, pp.601-608, 2017.

M. Inoue, K. Okajima, K. Itoh, Y. Ando, N. Watanabe et al., Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients, Kidney Int. août, vol.32, issue.2, pp.198-203, 1987.

G. D. Kitsios, P. Mascari, R. Ettunsi, and A. W. Gray, Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a metaanalysis, J Crit Care. avr, vol.29, issue.2, pp.253-262, 2014.

F. K. Triposkiadis, J. Butler, G. Karayannis, R. C. Starling, G. Filippatos et al., Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial, Int J Cardiol. 1 mars, vol.172, issue.1, pp.115-136, 2014.

W. Mullens, Z. Abrahams, H. N. Skouri, G. S. Francis, D. O. Taylor et al., Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function?, J Am Coll Cardiol. 22 janv, vol.51, issue.3, pp.300-306, 2008.

D. Zachariah and P. R. Kalra, Managing patients with cardiorenal syndrome: time to look to the gut?, Eur J Heart Fail. août, vol.14, issue.8, pp.870-872, 2012.

M. L. Cheatham, M. W. White, S. G. Sagraves, J. L. Johnson, and E. F. Block, Abdominal perfusion pressure: a superior parameter in the assessment of intra-abdominal hypertension, J Trauma, vol.49, issue.4, pp.626-627, 2000.

V. Q. Nguyen, T. V. Gadiraju, H. Patel, M. Park, T. Jemtel et al., Intra-abdominal Hypertension: An Important Consideration for Diuretic Resistance in Acute Decompensated Heart Failure, Clin Cardiol, vol.39, issue.1, pp.37-40, 2016.

J. Núñez, M. González, G. Miñana, R. Garcia-ramón, J. Sanchis et al., Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure, Eur J Heart Fail. mai, vol.14, issue.5, pp.540-548, 2012.

S. S. Gottlieb, A. Stebbins, A. A. Voors, V. Hasselblad, J. A. Ezekowitz et al., Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure), J Am Coll Cardiol. 24 sept, vol.62, issue.13, pp.1177-83, 2013.

A. F. Hernandez, C. M. O'connor, R. C. Starling, C. J. Reist, P. W. Armstrong et al., Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF), Am Heart J. févr, vol.157, issue.2, pp.271-278, 2009.

J. R. Teerlink, A. A. Voors, P. Ponikowski, P. S. Pang, B. H. Greenberg et al., Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study, Eur J Heart Fail, vol.19, issue.6, pp.800-809, 2017.

, Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study

D. Sur,

P. S. Pang, J. Butler, S. P. Collins, G. Cotter, B. A. Davison et al., Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF), Eur Heart J. 7 août, vol.38, issue.30, pp.2364-73, 2017.

N. D. Mdege, M. Man, T. N. Brown, C. A. Torgerson, and D. J. , Systematic review of stepped wedge cluster randomized trials shows that design is particularly used to evaluate interventions during routine implementation, J Clin Epidemiol. sept, vol.64, issue.9, pp.936-984, 2011.

D. Barker, P. Mcelduff, D. 'este, C. Campbell, and M. J. , Stepped wedge cluster randomised trials: a review of the statistical methodology used and available, BMC Med Res Methodol, vol.06, p.69, 2016.

M. J. Grayling, J. M. Wason, and A. P. Mander, Group sequential designs for stepped-wedge cluster randomised trials, Clin Trials Lond Engl, vol.14, issue.5, pp.507-524, 2017.

G. Adams, M. C. Gulliford, O. C. Ukoumunne, S. Eldridge, S. Chinn et al., Patterns of intra-cluster correlation from primary care research to inform study design and analysis, J Clin Epidemiol. août, vol.57, issue.8, pp.785-94, 2004.

S. M. Eldridge, D. Ashby, and S. Kerry, Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method, Int J Epidemiol, vol.35, issue.5, pp.1292-300, 2006.

K. Hemming, R. Lilford, and A. J. Girling, Stepped-wedge cluster randomised controlled trials: a generic framework including parallel and multiple-level designs, Stat Med. 30 janv, vol.34, issue.2, pp.181-96, 2015.

P. C. O'brien, Procedures for comparing samples with multiple endpoints, Biometrics. déc, vol.40, issue.4, pp.1079-87, 1984.

P. C. Austin, D. S. Lee, and J. P. Fine, Introduction to the Analysis of Survival Data in the Presence of Competing Risks, Circulation. 9 févr, vol.133, issue.6, pp.601-610, 2016.

I. Annexe, Protocole d'utilisation des diurétiques -D'après

I. I. Annexe, Formulaire de consentement et d'information de l'étude ProDUCT-HF (Conseil national de l'ordre des médecins)

. Serment-d'hippocrate,

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies

, Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses